Lymphangiogenesis in breast carcinoma is present but insufficient for metastatic spread by Dorić, Mirsad et al.
Mirsad Doriæ et al. Journal of Health Sciences 2014;4(1):4-11 http://www.jhsci.ba
Journal of Health Sciences 
© 2014 Mirsad Doriæ et al.; licensee University of Sarajevo - Faculty of Health Studies. This is 
an Open Access article distributed under the terms of the Creative Commons Attribution 
License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distri-
bution, and reproduction in any medium, provided the original work is properly cited.
UNIVERSITY OF SARAJEVO 
FACULTY OF HEALTH STUDIES
ABSTRACT
Introduction: The lymphatic vasculature is an important route for the metastatic spread of human cancer. 
However, the extent to which this depends on lymphangiogenesis or on invasion of existing lymph ves-
sels remains controversial. The goal of this study was to investigate the existence of lymphangiogenesis in 
invasive breast carcinoma: by measuring the lymphatic vessels density (LVD) and lymphatic endothelial cell 
proliferation (LECP) and their correlation with various prognostic parameters in breast cancer, including 
lymphovascular invasion (LVI). 
Methods: Lymphatic vessels density was investigated in 75 specimens of invasive breast carcinoma by 
immunostaining for D2-40 using the Chalkley counting method. Endothelial proliferation in lymphatic 
vessels was analyzed by dual-color immunohistochemistry with D2-40 and Ki-67.
Results: Decrease of intra and peritumoral LVD in invasive breast carcinoma compared to fi brocystic 
breast disease was detected (p=0.002). Lymphatic endothelial cell proliferation was signifi cantly higher 
in invasive breast cancer (p=0.008) than in the fi brocystic breast disease. LECP showed a correlation with 
histological grade of the tumor (p=0.05). Involvement of axillary lymph nodes with metastatic tissue was 
in strong correlation only with existence of lymphatic vascular invasion (p=0.0001). 
Conclusion: These results suggest that development of breast cancer promotes proliferation of lymphatic 
endothelial cells whose level correlates with histological grade of tumor, but in a scope that is insuffi cient 
to follow growth of tumor tissue that invades them and destruct them. This might explain the decrease 
of lymphatic vessels density.
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INTRODUCTION
Th e major cause of death from breast cancer is dis-
semination of the primary tumor leading to forma-
tion of metastases. Spread to axillary lymph nodes 
is often the fi rst step of generalization (1). Tumor-
associated lymphatic vessels are considered to be the 
main route of tumor cells to axillary lymph nodes 
(2). Recently, lymphangiogenesis, the formation of 
new lymphatic vessels, has become a new research 
frontier in tumor metastasis since the discovery of 
the two major lymphatic vessel growth factors-C 
(VEGF-C) and -D (VEGF-D), as well as reliable 
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lymphatic markers that have allowed observation 
and isolation of lymphatic endothelium (3).
Specifi c lymphatic endothelial markers have become 
available, making analysis of lymphatics in cancer 
possible. D2-40 antibody was reported to detect a 
fi xation-resistant epitope on a 40 kDa O-linked si-
aloglycoprotein expressed in lymphatic endothelium 
but not blood vessels, and can be used to assess lym-
phangiogenesis specifi cally in conventionally pro-
cessed formalin-fi xed and paraffi  n-embedded tissue 
specimens (4,5).
Although proliferating lymphatics, that promote 
nodal metastasis, have been demonstrated in experi-
mental breast tumors, it has yet to be determined 
whether the same phenomena occurs in spontaneous 
human breast cancers. Th e existence of lymphangio-
genesis in breast carcinoma is one of the most con-
troversial areas in the breast cancer literature.
Th e aim of this study was to investigate existence 
of lymphangiogenesis in invasive breast carcinoma: 
by measuring lymphatic vessels density (LVD) and 
lymphatic endothelial cell proliferation (LECP), 
and their correlation with various prognostic pa-
rameters in breast cancer, including lymphovascular 
invasion (LVI).
METHODS
Clinico-pathological data
Seventy-fi ve cases of invasive carcinoma (IC) of the 
breast were identifi ed by searching the database of 
the Institute of Pathology, Medical faculty of Sara-
jevo, Bosnia and Herzegovina. All patients with IC 
of the breast underwent partial or total mastectomy 
with axillary lymph node dissection. No neoadju-
vant chemotherapy or radiotherapy was adminis-
tered before the surgical treatment. Ten samples 
fi brocystic breast tissue were used as a control group.
Th e patient age at the time of surgery ranged from 
37 to 87 years, (mean 59.43 years). Clinicopatho-
logical characteristics of the studied cases are shown 
in Table 1.
Immunohistochemical staining
Double-labeling immunohistochemical staining. Four-
micron-thick paraffi  n sections were taken on charged 
slides, deparaffi  nized in xylene, and hydrated with 
graded alcohols and distilled water. To detect divid-
Variable Cases  (%)
Tumor size (AJCC)
   pT1 41 54.7
   pT2 32 42.7
   pT3 2 2.7
Tumor type
   Ductal (NOS) 57 76
   Lobular 8 10.7
   Medullary 4 5.3
 Neuroendocrine 3 4
 Mucinous 2 2.7
 Tubular 1 1.3
Grade
   1 23 30.7
   2 33 44
   3 19 25.3
ER status
   Positive 48 64.2
   Negative 27 35.8
PR status
   Positive 45 54.7
   Negative 30 45.3
HER2 status
   0 43 50.6
   1 + 13 15.3
   2 + 3 3.5
   3 + 16 18.8
Ki-67
   Negative 3 4
   Positive 72 96
bcl2
   Negative 41 54.7
   Positive 34 45.3
p53
   Negative 41 54.7
   Positive 34 45.3
Nodal status
   Negative 68 90.7
   Positive 7 9.3
Lymphovascular invasion (LVI)
   Negative 46 61.3
   Positive 29 38.7
TABLE 1.  Clinicopathological characteristics of the studied 
cases
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ing lymph vessel endothelial cells, a double immu-
nostaining for D2-40 and the proliferation marker 
Ki-67 was done. First, a monoclonal antibody di-
rected at Ki-67 (Dako Cytomation; dilution 1:60, 
klon MIB 1) was applied to the rehydrated paraf-
fi n sections for 15 minutes after antigen retrieval in 
TBS (tris)-EDTA buff er (pH 9.0) at 95°C. Sections 
were incubated with EnVision+ Dual Link solu-
tion before development with diaminobenzidine 
(Dako Cytomation). Sections were then stained 
with the D2-40 antibody (Dako Cytomation; dilu-
tion 1:100) for 60 minutes. EnVision System alka-
line phosphatase and Fast Red chromogen (Dako 
Cytomation) were used to visualize binding of this 
second antibody.
Immunostaining for ER, PR, HER2, p53, bcl-2 and 
Ki-67. Th e primary antibody against the estrogen 
receptor was performed in humidity chamber in 
EDTA buff er (pH 9) for 40 min. (clone 1D5, Dako 
Cytomation; dilution 1:30). Th e protocols for stain-
ing PR, Ki-67, and p53 included a microwave an-
tigen retrieval step, 3 times for 5 minutes: anti-PR 
(clone PgR, Dako Cytomation; dilution 1:30), anti-
Ki-67 (clon MIB-1, Dako Cytomation; dilution 
1:10), anti-p53 (clone DO-7, Dako Cytomation; 
dilution 1:5). Citrate buff er (pH 6) was used for 
anti-bcl-2 oncoprotein (clone 124, Dako Cytoma-
tion; dilution 1:40). Th e working system used was 
LSAB2 (labelled streptavidin biotin) – HRP and di-
aminobenzidine (DAB) was the chromogen used for 
reaction visualization. 
Antigen retrieval for HER2 using HercepTest was 
performed following the manufacturer's protocol 
(Dako Cytomation).
Immunohistochemistry evaluation. Th e percentage of 
tumor cells with unequivocal nuclear staining for 
estrogen receptor (ER), progesterone receptor (PR), 
p53, Ki-67 (MIB-1), was recorded semiquantita-
tively (0, no staining; 1, <10%; 2, 11-33%; 3, 34-
66%; 4, 67-100%). For Bcl-2 the intensity of cyto-
plasmic staining (0-4) and the percentage of positive 
cells were recorded. A cutoff  value was applied to 
each marker to indicate positive or negative staining. 
A threshold of ≥1% for ER, PR, and 10% for p53 
and Ki-67 (MIB-1) was used and score of 3+ for 
HER2. For Bcl-2, there was little diff erence between 
the diff erent measures of positivity (i.e., percentage 
of positive cells versus intensity of staining) and a 
cutoff  value of 10% was used. 
Membranous staining was scored for HER2 accord-
ing to the HercepTest (Dako) as follows: 0, no stain-
ing or faint incomplete staining in <10% cells; 1, 
faint incomplete staining in >10% cells; 2, weak to 
moderate complete staining in >10% cells; 3, strong 
complete staining in >10% cells. Cases scored as 2+ 
were considered equivocal, and retested using chro-
mogen in situ hybridization (CISH). 
Lymphatic vessels quantifi cation
Sections stained with D2-40 were used for the eval-
uation of LVD using the Chalkley counting method. 
Each section was fi rst scanned at low-power magni-
fi cation (×40) to select the most vascularized areas; 
three hot spots were selected. Two authors fi rst ex-
amined 10% of specimens to agree on which fi elds 
to be used as hot spots. A 25-point Chalkley eye-
piece graticule was applied to each hot spot and ori-
ented to permit the maximum number of points to 
hit on, or within the areas of immunohistochemical-
ly highlighted microvessel using ×200 magnifi cation. 
A Chalkley count for an individual tumor was taken 
as the mean value of the three graticule counts (6).
Assessment of lymphatic endothelial cell pro-
liferation
Th e fractions of proliferating lymphatic endothelial 
cells (LECP%) were calculated in each hotspot as 
the number of lymphatic endothelial cells with Ki-
67stained nuclei per 100 lymphatic endothelial cells. 
Cases in which the average number of lymphatic 
endothelial cells in three hotspots was <10 were ex-
cluded for statistical analysis.
STATISTICAL ANALYSIS
Statistical analysis was performed using SPSS for 
Windows (version 13; SPSS, Chicago, Il, USA). 
Two-tailed unpaired t test was performed to iden-
tify the diff erences between two groups. One-way 
ANOVA test was performed for comparing the 
groups that were used for the t test. Th e correlations 
between the variables were assessed by the Spearman 
rank sum test. P values <0.05 were considered as sta-
tistically signifi cant. 
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RESULTS 
Benign breast samples
In these 10 cases, the lymphatic vessels were dis-
persed around the lobules in the interlobular stroma, 
adipose tissue, and adjacent to blood vessels. Th ese 
vessels were elongated and linear in most areas and 
tortuous focally. Lymphatic vessels were not iden-
tifi ed within the intralobular stroma (Figure 1A). 
Lymphatic endothelial cell proliferation was ob-
served in 3 of 10 cases.
Invasive carcinoma
Lymphatic vessels were identifi ed within invasive 
tumors except in areas adjacent to preexisting ducts 
and lobules; the latter were interpreted as preexist-
ing vessels ‘entrapped’ within the tumor (Figure 
1B). Blood vessels within the tumor mass were not 
associated with perivascular lymphatic vessels. Th e 
density of intratumoral and peritumoral lymphatic 
vessels in invasive carcinoma was signifi cantly lower 
(p=0.002) in comparison to fi brocystic disease (Fig-
ure 2). Conversely, density of peritumoral lymphatic 
vessels was signifi cantly higher in comparison to in-
tratumoral lymphatic vessel density (p=0.0001).
FIGURE 1.  (A) The lymphatic vessels were elongated and linear, dispersed around the lobules in the interlobular stroma (D2-40 
x 100). (B) D2-40/Ki-67 positive peritumoural lymphatic vessels (x 100)
FIGURE 2.  Decrease of intra and peritumoral LVD in inva-
sive breast carcinoma compared to fi brocystic breast disease 
(p=0.002).
FIGURE 3.  LECP show correlation with histological grade of 
the tumor (p=0.05).
A                     B
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Lymphatic endothelial cell proliferation was ob-
served in the fi brocystic breast disease (in 3 of 10 
cases) but was signifi cantly higher (p=0.008) in 
invasive breast cancer. LECP% showed correlation 
(p=0.05) with histological grade of the tumor (Fig-
ure 3). Signifi cant correlation was not found be-
tween lymphatic vascular density and lymphatic en-
dothelial cell proliferation. Involvement of axillary 
lymph nodes with metastatic tissue showed strong 
correlation (p=0.0001) only with existence of lym-
phatic vascular invasion (Figure 4).
DISCUSSION
Th e invasion and metastasis of tumor cells are im-
portant biological features of neoplasm and the main 
cause for poor prognosis and death (7). Axillary 
lymph node status at time of diagnosis is the most 
signifi cant and durable prognostic factor in breast 
cancer patients (1). However, the extent to which 
this depends on lymphangiogenesis or on invasion 
of existing lymph vessels remains controversial.
Lymphangiogenesis may be assessed either by LVD 
or lymphatic endothelial proliferation. In the cur-
rent study, lymphangiogenesis was assessed by both 
these methods. We did not fi nd an increased LVD 
in breast cancer. Dual immunohistochemistry us-
ing D2-40 and Ki-67 showed expression of Ki-67 
in lymphatic endothelial cells indicating prolifera-
tion. Th e results of the present study confi rmed Ki-
67-positive nuclei in a proportion of lymph vessel 
endothelial cells, suggesting that there is indeed 
lymphangiogenesis in breast cancer, the most com-
pelling evidence being the presence of proliferating 
lymphatic endothelial cells.
Vleugel et al. (8) and Williams et al. (9) failed to 
detect lymphangiogenesis in breast cancer using 
LYVE-1 as a marker for lymphatic vessels. Williams 
et al. (9) did not fi nd ‘dividing’ lymphatic vessels 
within the tumor in their analysis of 75 cases of in-
vasive ductal and lobular breast cancer using dual 
immunohistochemistry for LYVE-1 and Ki-67. In 
contrast, Choi et al. (10) studied LVD without dif-
ferentiating between intratumoral and peritumoral 
lymphatic vessels in breast cancer using D2-40 an-
tibody. Th ey found that increased LVD correlated 
with several prognostic factors, including lymph 
node metastasis. Bono et al. (11) found intratumor-
al LYVE-1-positive vessels in only 12% of cases, in 
contrast of fi nding such vessels in a peritumoral lo-
cation in 94% of cases. Increased number of peritu-
moral lymphatic vessels were associated with a poor 
outcome. Th ese results are similar to those of Naka-
mura et al. (12) who found increased fl t-4-positive 
vessel density to be associated with VEGF-D expres-
sion, positive nodal status, and poor prognosis.
Detection of dividing lymphatic endothelial cells 
became central to the current controversy on 
whether lymphangiogenesis occurs in breast cancer 
and whether lymphatic metastasis occurs through 
pre-existing or newly-formed lymphatic vessels 
(13-15). Th is controversy exists because neither the 
mere presence of pro-lymphangiogenic factors nor 
frequent incidence of lymph node metastasis con-
stitutes a proof of tumor-induced, actively ongoing 
formation of new lymphatic vessels. Resolving this 
question has been sought by double staining using 
antibodies to specifi c lymphatic markers (LYVE-1 
or D2-40) combined with antibodies to prolifera-
tive markers such Ki-67 (MIB-1) or PCNA. As a re-
sult, interpretation of overlapped lymphatic marker/
Ki-67 positivity might depend on whether the posi-
FIGURE 4.  Axillary lymph node metastasis showed strong 
correlation only with existence of lymphatic vascular invasion 
(p=0.0001).
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tive cells are seen to be proliferating LEC, or divid-
ing tumor cells that had invaded lymphatic vessels. 
Additional challenges in detection of proliferating 
LEC are: (a) a relatively low rate of vessel formation 
in well-established tumors; (b) a lower density and 
heterogeneity of tumor lymphatics compared with 
tumor blood vessels; and (c) variability in sprouting 
of new vessels at diff erent points along the parental 
lymphatic vessel (16), with the latter being unde-
tectable in two-dimensional evaluation. Moreover, 
the formation of new lymphatic vessels might not 
require endothelial mitotic division if they originate 
from circulating progenitors or non-endothelial 
cells via trans-diff erentiation (17).
Given these technical and biological limitations, it is 
not surprising that several studies failed to detect Ki-
67 or PCNA markers on LYVE-1 or D2-40-labeled 
structures (13-15). However, evidence from several 
research groups also supports tumor-induced lym-
phangiogenesis and shows its clinical relevance to 
lymphatic metastasis. For instance, double Ki-67/
podoplanin staining of a large panel (N= 177) of 
invasive breast carcinomas determined that 29% 
of specimens displayed Ki-67 positive nuclei in 
2.2% of intratumoral, peritumoral and peripheral 
lymphatics (18). Frequency of positive nuclei was 
strongly associated with a high lymphatic density 
(p = 0.001), LN metastasis and survival (18). An 
independent study detected a similar fraction of 
proliferating LEC (LECP%) in peritumoral lym-
phatics also identifi ed LECP% as an independent 
prognostic factor for LN metastasis (19). Studies 
that compared LECP% in infl ammatory and non-
infl ammatory breast cancers found that the former 
have both a higher incidence of Ki-67 positive lym-
phatics (80% vs. 50%) and an increased median 
LECP% (20, 21). Active lymphangiogenesis was 
also detected in positive sentinel LN (22, 23) that 
displayed a signifi cantly higher median LECP% (p 
< 0.001) than uninvolved LN (23). Moreover, high 
frequency of Ki-67-labeled lymphatics in positive 
sLN was strongly associated (p = 0.01) with axillary 
metastasis (22), supporting the contention that tu-
mor-induced lymphangiogenesis promotes dissemi-
nation from both the primary tumor and secondary 
metastatic sites. Nevertheless, with the exception 
of very active lymphangiogenesis in infl ammatory 
breast cancer (20,21), a relatively low fraction of di-
viding lymphatic endothelial cells (2–6%) and some 
discrepancy between high %LVI and low %LECP 
in other breast cancer types suggest that both new 
and existing lymphatic vessels partake in lymphatic 
metastasis (24).
In contrast to challenges mentioned earlier in the 
detection of dividing LEC, enumerating lymphatic 
vessels seemed initially a straightforward measure 
of lymphangiogenesis. To assess tumor vascularity, 
there are several methods including counting the 
number of immunohistochemically stained mi-
crovessels in vascular hot spots, grading of vascular, 
using image analysis systems (25) and applying the 
Chalkley grid. Th e Chalkley count technique was 
recommended in an international consensus report 
because it is considered to be a simple and accept-
able procedure for daily clinical use and produced 
lower inter-observer variability compared to the 
more frequently used conventional microvessel den-
sity method (26). LVD has been studied in a num-
ber of human cancers, including melanoma (27) 
and prostate (28). As a result, fi ndings and interpre-
tations from the studies that focused on infrequently 
occurring intratumoral lymphatic vessels (14), or 
those that compared a heterogeneous LVD pattern 
to more orderly tumor blood vessel distribution 
(13), fueled the debate whether lymphangiogenesis 
exists in breast cancer (13-15). Additional complex-
ity arises from the fact that, in contrast to blood ves-
sels, lymphatic vessels support spread of metastatic 
cells, but not tumor cell proliferation and expansion 
of the tumor mass. Kanngurn et al. (29) showed 
that microvessel density (MVD) Chalkley but not 
the LVD Chalkley count can be a predictive factor 
for axillary lymph node metastasis in breast carci-
noma. Th erefore, subtle increases in LVD might be 
missed in tumor sections set aside for immunohis-
tochemical analysis, although they might suffi  ce for 
tumor dissemination in a patient. All methods used 
in study of Niemiec et al. (30) for assessment of lym-
phangiogenesis (LVD, DLV, LVD/MVD) were cor-
related to each other and to parameters indicating 
aggressive tumor behavior (high grade, TNP, HER2 
subtype, basal marker expression), hence they might 
be used equivalently.
Th e main evidence supporting the claim that lym-
phangiogenesis does not exist in tumors is detection 
of decreased LVD or absence of intratumoral lym-
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phatic vessels (LV) compared with normal breast tis-
sue (13-15). Th e same studies, however, reported a 
signifi cant increase (p=0.0001) in peritumoral LVD 
(13,15) with some lymphatic vessels containing tu-
mor emboli (13). Th ere is a wide range of opinions 
with regard to a prognostic value of intratumoral 
LVD. However, a consensus seems to exist with re-
gard to increased density of peritumoral lymphatic 
vessels that might be suffi  cient for tumor cell transit 
to lymph node even in the absence of intratumoral 
lymphatics.
CONCLUSION
Th e fi ndings from this study show that lymphan-
giogenesis in breast cancers, measured by lymphatic 
endothelial cell proliferation is present, but mea-
sured by lymphatic vascular density is absent. Th ese 
results suggest that development of cancer tissue in 
breast promotes proliferation of lymphatic endo-
thelial cells whose level correlates with histological 
grade of tumor, but in a scope that is insuffi  cient 
to follow growth of tumor tissue that invades them 
and destruct them. Th is might explain decrease of 
lymphatic vessels density.
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